Peresolimab shows promise for rheumatoid arthritis in Phase 2a trial

In a significant breakthrough, a phase 2a clinical trial has shown promising results for Peresolimab, a humanized IgG1 monoclonal antibody designed to stimulate the endogenous programmed cell death protein 1 (PD-1) inhibitory pathway in patients with autoimmune or autoinflammatory diseases, with a focus on rheumatoid arthritis. The double-blind, randomized, placebo-controlled...